Ovid Therapeutics Inc. (OVID)

3,3400 +0,1100 (+3,41%) A partir del 03:00PM EDT. Mercado abierto.

Ovid Therapeutics Inc.

41 Ninth Avenue
14th Floor
New York, NY 10001
United States
646 661 7661
https://www.ovidrx.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 40

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir	President, CEO & Chairman	1,03M	N/A	1953
Mr. Jeffrey A. Rona	Chief Business and Financial Officer	761,24k	N/A	1968
Mr. Thomas Michael Perone J.D., M.B.A.	General Counsel, Chief Compliance Officer & Corporate Secretary	745,71k	N/A	1965
Mr. Jason Tardio M.B.A.	Chief Operating Officer	652,84k	N/A	1977
Mr. Simon D. Kelner	Chief Human Resources Officer	N/A	N/A	1974
Dr. Dirk Haasner	Senior Vice President of Global Manufacturing & CMC QA	416,95k	N/A	1965
Dr. Todd F. Baumgartner M.D., M.P.H.	Senior Vice President of Regulatory Affairs	N/A	N/A	N/A
Dr. Julia Tsai Ph.D.	Senior Vice President of Clinical Development	N/A	N/A	1975
Ms. Meg Alexander	Chief Strategy Officer	N/A	N/A	N/A
Dr. Manoj Malhotra M.D.	Chief Medical Officer	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Gobierno corporativo

El ISS Governance QualityScore de Ovid Therapeutics Inc., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 8; Tablero: 8; Derechos de los accionistas: 7; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.